loading page

Demonstrating drug treatment efficacies by monitoring superoxide dynamics in human lung cancer cells with time-lapse fluorescence microscopy
  • +5
  • Shalaka Konjalwar,
  • Busenur Ceyhan,
  • Oscar Rivera,
  • Parisa Nategh,
  • Mehrnoosh Neghabi,
  • Mirjana Pavlovic,
  • Shailaja Allani,
  • Mahsa Ranji
Shalaka Konjalwar
Florida Atlantic University
Author Profile
Busenur Ceyhan
Florida Atlantic University
Author Profile
Oscar Rivera
Florida Atlantic University
Author Profile
Parisa Nategh
Florida Atlantic University
Author Profile
Mehrnoosh Neghabi
Florida Atlantic University
Author Profile
Mirjana Pavlovic
Florida Atlantic University
Author Profile
Shailaja Allani
Florida Atlantic University
Author Profile
Mahsa Ranji
Florida Atlantic University

Corresponding Author:[email protected]

Author Profile

Abstract

Metformin hydrochloride, an antihyperglycemic agent, and sulindac, a nonsteroidal anti-inflammatory drug, are FDA-approved drugs known to exert anticancer effects. Previous studies demonstrated sulindac and metformin’s anticancer properties through mitochondrial dysfunction and inhibition of mitochondrial electron transport chain (ETC) complex I, as well as key signaling pathways. In this study, various drugs were adminsitered to A549 lung cancer cells, and results revealed that a combination of sulindac and metformin enhanced cell death compared to administration of the drugs separately. To measure superoxide production over time, we employed a time-lapse fluorescence imaging technique using mitochondrial-targeted hydroethidine. Fluorescence microscopy data showed largest increases in superoxide production in the combination treatment of metformin and sulindac. Results showed significant differences between the combined drug treatment and control groups, as well as between the positive control and control groups. This approach can be utilized to quantify anticancer efficacy of drugs, creating possibilities for additional therapeutic options.
21 Aug 2023Submitted to Journal of Biophotonics
21 Aug 2023Submission Checks Completed
21 Aug 2023Assigned to Editor
21 Aug 2023Review(s) Completed, Editorial Evaluation Pending
21 Aug 2023Reviewer(s) Assigned
13 Sep 2023Editorial Decision: Revise Major
04 Oct 20231st Revision Received
04 Oct 2023Reviewer(s) Assigned
04 Oct 2023Submission Checks Completed
04 Oct 2023Assigned to Editor
04 Oct 2023Review(s) Completed, Editorial Evaluation Pending
05 Oct 2023Editorial Decision: Accept